Cargando…

HDAC inhibitors enhance the anti-tumor effect of immunotherapies in hepatocellular carcinoma

Hepatocellular carcinoma (HCC), the most common liver malignancy with a poor prognosis and increasing incidence, remains a serious health problem worldwide. Immunotherapy has been described as one of the ideal ways to treat HCC and is transforming patient management. However, the occurrence of immun...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shen, Chen, Li, Mei, Duan, Yujuan, Jiang, Xin, Hou, Xiaoming, Xue, Fulai, Zhang, Yinan, Luo, Yao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10250615/ https://www.ncbi.nlm.nih.gov/pubmed/37304265 http://dx.doi.org/10.3389/fimmu.2023.1170207

Ejemplares similares

Abrine, an IDO1 inhibitor, suppresses the immune escape and enhances the immunotherapy of anti-PD-1 antibody in hepatocellular carcinoma
por: Liang, Xiaowei, et al.
Publicado: (2023)

HDAC inhibitors enhance the immunotherapy response of melanoma cells
por: Booth, Laurence, et al.
Publicado: (2017)

Elucidating the direct effects of the novel HDAC inhibitor bocodepsin (OKI-179) on T cells to rationally design regimens for combining with immunotherapy
por: Holay, Nisha, et al.
Publicado: (2023)

Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study
por: Li, Shuqun, et al.
Publicado: (2023)

Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects
por: Liu, Zhuoyan, et al.
Publicado: (2021)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy
por: Wu, Jianmin, et al.
Publicado: (2021)

Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study
por: Shen, Jianming, et al.
Publicado: (2022)

Functional Inhibition of Host Histone Deacetylases (HDACs) Enhances in vitro and in vivo Anti-mycobacterial Activity in Human Macrophages and in Zebrafish
por: Moreira, Jôsimar D., et al.
Publicado: (2020)

HDAC inhibitors Panobinostat and Romidepsin enhance tax transcription in HTLV-1-infected cell lines and freshly isolated patients’ T-cells
por: Schnell, Annika P., et al.
Publicado: (2022)

HDAC inhibitors and immunotherapy; a double edged sword?
por: Kroesen, Michiel, et al.
Publicado: (2014)

Bibliometric study of immunotherapy for hepatocellular carcinoma
por: Li, Zhiyi, et al.
Publicado: (2023)

Case Report: Durable complete response of metastatic hepatocellular carcinoma with asymptomatic hyperamylasemia to combined immunotherapy of anti-cytotoxic T lymphocyte-associated antigen 4 plus anti-programmed cell death-1 antibodies
por: Gao, Han, et al.
Publicado: (2023)

Synergistic Tumor Cytolysis by NK Cells in Combination With a Pan-HDAC Inhibitor, Panobinostat
por: Afolabi, Lukman O., et al.
Publicado: (2021)

Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies
por: Giraud, Julie, et al.
Publicado: (2021)

Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?
por: Jiang, Jingyu, et al.
Publicado: (2023)

Prognostic signatures of sphingolipids: Understanding the immune landscape and predictive role in immunotherapy response and outcomes of hepatocellular carcinoma
por: Zhang, Xin, et al.
Publicado: (2023)

Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma
por: Hirano, Mitsuhito, et al.
Publicado: (2021)

Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma
por: Bensaid, Douae, et al.
Publicado: (2018)

HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma
por: Wang, Xiaoguang, et al.
Publicado: (2020)

Nanoparticle-based drug delivery systems to enhance cancer immunotherapy in solid tumors
por: Zhang, Jiaxin, et al.
Publicado: (2023)

Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma
por: Xing, Rui, et al.
Publicado: (2021)

Immunotherapy of hepatocellular carcinoma: recent progress and new strategy
por: Li, Jiarui, et al.
Publicado: (2023)

Estrogen Reverses HDAC Inhibitor-Mediated Repression of Aicda and Class-Switching in Antibody and Autoantibody Responses by Downregulation of miR-26a
por: Casali, Paolo, et al.
Publicado: (2020)

A contrast-enhanced ultrasound-based nomogram for the prediction of therapeutic efficiency of anti-PD-1 plus anti-VEGF agents in advanced hepatocellular carcinoma patients
por: Sun, Chao, et al.
Publicado: (2023)

TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy
por: Qiu, Hui, et al.
Publicado: (2021)

The transdermal cream of Formestane anti-breast cancer by controlling PI3K-Akt pathway and the tumor immune microenvironment
por: Gao, Lanyang, et al.
Publicado: (2023)

DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma
por: Chen, Yunfei, et al.
Publicado: (2021)

Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study
por: Yan, Zheng, et al.
Publicado: (2021)

Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma
por: Chen, Yue, et al.
Publicado: (2022)

Viral Status and Efficacy of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis
por: Ding, Ziniu, et al.
Publicado: (2021)

Attenuation of Rheumatoid Inflammation by Sodium Butyrate Through Reciprocal Targeting of HDAC2 in Osteoclasts and HDAC8 in T Cells
por: Kim, Da Som, et al.
Publicado: (2018)

Advanced diagnostic and therapeutic strategies in nanotechnology for lung cancer
por: Duan, Yujuan, et al.
Publicado: (2022)

Current insights into the hepatic microenvironment and advances in immunotherapy for hepatocellular carcinoma
por: Zhao, Ming, et al.
Publicado: (2023)

Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer
por: Liu, Chao, et al.
Publicado: (2021)

Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity
por: Seliger, Barbara
Publicado: (2019)

Prognostic model of immune checkpoint inhibitors combined with anti-angiogenic agents in unresectable hepatocellular carcinoma
por: Li, Xiaomi, et al.
Publicado: (2022)

YY1 promotes HDAC1 expression and decreases sensitivity of hepatocellular carcinoma cells to HDAC inhibitor
por: Dong, Sheng, et al.
Publicado: (2017)

Identification of cell senescence molecular subtypes in prediction of the prognosis and immunotherapy of hepatitis B virus-related hepatocellular carcinoma
por: Yu, Xue, et al.
Publicado: (2022)

Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study
por: Zhang, Weihao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hqpg1i5l0f6e4m7pog3gm4nub2